

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

Claim 1 (currently amended): A pharmaceutical preparation which comprises 2-(imidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid or a pharmacologically acceptable salt thereof in combination with ~~N-[2-cyano-4-(2,2-dimethyl-propylamino)-pyrimidin-5-ylmethyl]-4-(4-methyl-piperazin-1-yl)-benzamide~~ N-[1-(cyanomethyl-carbamoyl)-cyclohexyl]-4-[4-(1-propyl)-piperazin-1-yl]-benzamide or a pharmacologically acceptable salt thereof for simultaneous, sequential or separate use.

Claim 2 (currently amended): The pharmaceutical preparation according to claim 1 ~~wherein its use is for the treatment of malignant diseases, bone metastasis, cancer cell growth, or/and cancer therapy-induced bone loss.~~

Claim 3 (previously presented): A method of treating a patient suffering from bone metastasis, comprising administering to the patient an effective amount of the pharmaceutical preparation according to claim 1.

Claim 4 (canceled)

Claim 5 (currently amended): A pharmaceutical composition which comprises 2-(imidazol-1-yl)-1 hydroxyethane-1-1-disphosphonic acid or a pharmacologically acceptable salt thereof in combination with ~~comprising zoledronic acid and a cathepsin K inhibitor for the inhibition of bone metastasis, cancer cell growth or/and inhibition of cancer therapy-induced bone loss. or~~ a pharmacologically acceptable salt thereof for simultaneous, sequential or separate use wherein the cathepsin K inhibitor is selected from the group consisting of N-[1-(cyanomethyl-carbamoyl)-cyclohexyl]-4-[4-(1-propyl)-piperazin-1-yl]-benzamide.

Claims 6-7 (canceled)

Claim 8 (new) The pharmaceutical preparation according to claim 1 wherein the pharmacologically acceptable salt of N-[1-(cyanomethyl-carbamoyl)-cyclohexyl]-4-[4-(1-propyl)-piperazin-1-yl]-benzamide is hydrogen maleate.